[
  {
    "ts": null,
    "headline": "Gilead Sciences’s (NASDAQ:GILD) Q4 CY2025 Sales Beat Estimates",
    "summary": "Biopharmaceutical company Gilead Sciences (NASDAQ:GILD) reported Q4 CY2025 results exceeding the market’s revenue expectations, with sales up 5.2% year on year to $7.93 billion. On the other hand, the company’s full-year revenue guidance of $29.8 billion at the midpoint came in 1.2% below analysts’ estimates. Its non-GAAP profit of $1.86 per share was 1.9% above analysts’ consensus estimates.",
    "url": "https://finnhub.io/api/news?id=28f76eb098fe7f0bfa39afbe6d982bbb66384486c682d0555bbe3ec33e73ed43",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770758240,
      "headline": "Gilead Sciences’s (NASDAQ:GILD) Q4 CY2025 Sales Beat Estimates",
      "id": 139036347,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "GILD",
      "source": "Yahoo",
      "summary": "Biopharmaceutical company Gilead Sciences (NASDAQ:GILD) reported Q4 CY2025 results exceeding the market’s revenue expectations, with sales up 5.2% year on year to $7.93 billion. On the other hand, the company’s full-year revenue guidance of $29.8 billion at the midpoint came in 1.2% below analysts’ estimates. Its non-GAAP profit of $1.86 per share was 1.9% above analysts’ consensus estimates.",
      "url": "https://finnhub.io/api/news?id=28f76eb098fe7f0bfa39afbe6d982bbb66384486c682d0555bbe3ec33e73ed43"
    }
  },
  {
    "ts": null,
    "headline": "Gilead: Q4 Earnings Snapshot",
    "summary": "On a per-share basis, the Foster City, California-based company said it had net income of $1.74. Earnings, adjusted for one-time gains and costs, came to $1.86 per share. The results topped Wall Street expectations.",
    "url": "https://finnhub.io/api/news?id=6fd756bf37e9442717f0753b3644e5cbd01429c3520b223bdebdaf7af37b5a81",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770758017,
      "headline": "Gilead: Q4 Earnings Snapshot",
      "id": 139036348,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "GILD",
      "source": "Yahoo",
      "summary": "On a per-share basis, the Foster City, California-based company said it had net income of $1.74. Earnings, adjusted for one-time gains and costs, came to $1.86 per share. The results topped Wall Street expectations.",
      "url": "https://finnhub.io/api/news?id=6fd756bf37e9442717f0753b3644e5cbd01429c3520b223bdebdaf7af37b5a81"
    }
  },
  {
    "ts": null,
    "headline": "Will Gilead's Solid Fourth Quarter Be Enough To Shake Off Its Light Outlook?",
    "summary": "Gilead Sciences cleanly beat fourth-quarter expectations late Tuesday, but Gilead stock took a hit on its light guidance for 2026.",
    "url": "https://finnhub.io/api/news?id=63eb923a59df2f2613a01b12ddcf0712c96fbb4c8766795902bfaf5ef6a77047",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770757980,
      "headline": "Will Gilead's Solid Fourth Quarter Be Enough To Shake Off Its Light Outlook?",
      "id": 139036349,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "GILD",
      "source": "Yahoo",
      "summary": "Gilead Sciences cleanly beat fourth-quarter expectations late Tuesday, but Gilead stock took a hit on its light guidance for 2026.",
      "url": "https://finnhub.io/api/news?id=63eb923a59df2f2613a01b12ddcf0712c96fbb4c8766795902bfaf5ef6a77047"
    }
  },
  {
    "ts": null,
    "headline": "Gilead Sciences Announces 3.8 Percent Increase in First Quarter 2026 Dividend",
    "summary": "FOSTER CITY, Calif., February 10, 2026--Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the company’s Board of Directors has declared an increase of 3.8% in the company’s quarterly cash dividend, beginning in the first quarter of 2026. The increase will result in a quarterly dividend of $0.82 per share of common stock. The dividend is payable on March 30, 2026, to stockholders of record at the close of business on March 13, 2026. Future dividends will be subject to Board approval.",
    "url": "https://finnhub.io/api/news?id=3e25b7a9b5cd38ebf667d1efd6c3764843de19e5d6d42be4228eac7039294b73",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770757320,
      "headline": "Gilead Sciences Announces 3.8 Percent Increase in First Quarter 2026 Dividend",
      "id": 139036350,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "GILD",
      "source": "Yahoo",
      "summary": "FOSTER CITY, Calif., February 10, 2026--Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the company’s Board of Directors has declared an increase of 3.8% in the company’s quarterly cash dividend, beginning in the first quarter of 2026. The increase will result in a quarterly dividend of $0.82 per share of common stock. The dividend is payable on March 30, 2026, to stockholders of record at the close of business on March 13, 2026. Future dividends will be subject to Board approval.",
      "url": "https://finnhub.io/api/news?id=3e25b7a9b5cd38ebf667d1efd6c3764843de19e5d6d42be4228eac7039294b73"
    }
  },
  {
    "ts": null,
    "headline": "Gilead Sciences Announces Fourth Quarter and Full Year 2025 Financial Results",
    "summary": "FOSTER CITY, Calif., February 10, 2026--Gilead Sciences, Inc. (Nasdaq: GILD) announced today its results of operations for the fourth quarter and full year 2025.",
    "url": "https://finnhub.io/api/news?id=e3f9563ea9a614f63297cb8f6be4ac81a0bf3e115ae0a5d2802b901e52861f58",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770757260,
      "headline": "Gilead Sciences Announces Fourth Quarter and Full Year 2025 Financial Results",
      "id": 139036351,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "GILD",
      "source": "Yahoo",
      "summary": "FOSTER CITY, Calif., February 10, 2026--Gilead Sciences, Inc. (Nasdaq: GILD) announced today its results of operations for the fourth quarter and full year 2025.",
      "url": "https://finnhub.io/api/news?id=e3f9563ea9a614f63297cb8f6be4ac81a0bf3e115ae0a5d2802b901e52861f58"
    }
  },
  {
    "ts": null,
    "headline": "Earnings, Macro Data Leave Equity Markets Mixed Intraday",
    "summary": "US benchmark equity indexes were mixed intraday as traders evaluated the latest batch of corporate e",
    "url": "https://finnhub.io/api/news?id=315755cd07829694d3704e67f42e6659315b0320d64b576e2bbaf69d370a1f6f",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770750436,
      "headline": "Earnings, Macro Data Leave Equity Markets Mixed Intraday",
      "id": 139034903,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "GILD",
      "source": "Yahoo",
      "summary": "US benchmark equity indexes were mixed intraday as traders evaluated the latest batch of corporate e",
      "url": "https://finnhub.io/api/news?id=315755cd07829694d3704e67f42e6659315b0320d64b576e2bbaf69d370a1f6f"
    }
  },
  {
    "ts": null,
    "headline": "Stock Market Today, Feb: 10: Dow hits intraday record after retail sales disappoint",
    "summary": "This live blog is refreshed periodically throughout the day with the latest updates from the market.To find the latest Stock Market Today threads, click here. Happy Tuesday. This is TheStreet’s Stock Market Today for Feb. 10, 2025. You can follow the latest updates on the market ...",
    "url": "https://finnhub.io/api/news?id=c68da64b5ccf50aee501c4db61debe1bb9e9ca33beee13974b6f0c2843f1f5e1",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770745028,
      "headline": "Stock Market Today, Feb: 10: Dow hits intraday record after retail sales disappoint",
      "id": 139036352,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "GILD",
      "source": "Yahoo",
      "summary": "This live blog is refreshed periodically throughout the day with the latest updates from the market.To find the latest Stock Market Today threads, click here. Happy Tuesday. This is TheStreet’s Stock Market Today for Feb. 10, 2025. You can follow the latest updates on the market ...",
      "url": "https://finnhub.io/api/news?id=c68da64b5ccf50aee501c4db61debe1bb9e9ca33beee13974b6f0c2843f1f5e1"
    }
  },
  {
    "ts": null,
    "headline": "Stocks Rise Pre-Bell as Investors Await More Earnings, Retail Sales Report",
    "summary": "US equity futures were pointing higher on Tuesday as traders await the latest batch of corporate ear",
    "url": "https://finnhub.io/api/news?id=da0c1a9981d3ee824519b3b5ad561e15a0b186f873465d095cd6028fe260e43b",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770727207,
      "headline": "Stocks Rise Pre-Bell as Investors Await More Earnings, Retail Sales Report",
      "id": 139029505,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "GILD",
      "source": "Yahoo",
      "summary": "US equity futures were pointing higher on Tuesday as traders await the latest batch of corporate ear",
      "url": "https://finnhub.io/api/news?id=da0c1a9981d3ee824519b3b5ad561e15a0b186f873465d095cd6028fe260e43b"
    }
  },
  {
    "ts": null,
    "headline": "FDA Yescarta Decision Fuels Questions On Gilead Valuation And Momentum",
    "summary": "FDA removes prior limitations on Gilead Sciences' Yescarta for relapsed or refractory primary central nervous system lymphoma. Yescarta becomes the only CAR T cell therapy with this status for relapsed or refractory large B cell lymphoma. The decision broadens the eligible patient pool for a rare and difficult to treat lymphoma subtype. Gilead Sciences, NasdaqGS:GILD, is drawing fresh attention after the FDA cleared a wider path for its Yescarta cell therapy in challenging lymphoma cases...",
    "url": "https://finnhub.io/api/news?id=b185a354b4148ce670a457f304d36b762927311254877e237b28115e0fa3137b",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770721796,
      "headline": "FDA Yescarta Decision Fuels Questions On Gilead Valuation And Momentum",
      "id": 139028430,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "GILD",
      "source": "Yahoo",
      "summary": "FDA removes prior limitations on Gilead Sciences' Yescarta for relapsed or refractory primary central nervous system lymphoma. Yescarta becomes the only CAR T cell therapy with this status for relapsed or refractory large B cell lymphoma. The decision broadens the eligible patient pool for a rare and difficult to treat lymphoma subtype. Gilead Sciences, NasdaqGS:GILD, is drawing fresh attention after the FDA cleared a wider path for its Yescarta cell therapy in challenging lymphoma cases...",
      "url": "https://finnhub.io/api/news?id=b185a354b4148ce670a457f304d36b762927311254877e237b28115e0fa3137b"
    }
  },
  {
    "ts": null,
    "headline": "Stocks to Watch Tuesday: Coca-Cola, Onsemi, Ford",
    "summary": "↘️ On Semiconductor (ON): The chip company missed quarterly revenue forecasts, with sales declining in its two biggest businesses. Shares dropped 4% in premarket trading. ? Coca-Cola (KO), Marriott (MAR), Spotify (SPOT) and S&P Global (SPGI) are among the companies due to report results ahead of the open.",
    "url": "https://finnhub.io/api/news?id=ec6711260a5e02248db330bbc0ddd6e5ce42727c8ea6fe55d8360b7d8077aeba",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770719317,
      "headline": "Stocks to Watch Tuesday: Coca-Cola, Onsemi, Ford",
      "id": 139028403,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "GILD",
      "source": "Yahoo",
      "summary": "↘️ On Semiconductor (ON): The chip company missed quarterly revenue forecasts, with sales declining in its two biggest businesses. Shares dropped 4% in premarket trading. ? Coca-Cola (KO), Marriott (MAR), Spotify (SPOT) and S&P Global (SPGI) are among the companies due to report results ahead of the open.",
      "url": "https://finnhub.io/api/news?id=ec6711260a5e02248db330bbc0ddd6e5ce42727c8ea6fe55d8360b7d8077aeba"
    }
  },
  {
    "ts": null,
    "headline": "Cisco Earnings, Jobs Report, CPI Data: What to Watch This Week",
    "summary": "This week brings a deluge of economic indicators, particularly jobs and inflation reports, which were stalled by the recent government shutdown. Investors will also navigate earnings reports and appearances by Federal Reserve policymakers.",
    "url": "https://finnhub.io/api/news?id=09dc89d140df93db072192a7dce137b123b4ee5e8199dc97540e0c129bafedd7",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770711269,
      "headline": "Cisco Earnings, Jobs Report, CPI Data: What to Watch This Week",
      "id": 139027740,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "GILD",
      "source": "Yahoo",
      "summary": "This week brings a deluge of economic indicators, particularly jobs and inflation reports, which were stalled by the recent government shutdown. Investors will also navigate earnings reports and appearances by Federal Reserve policymakers.",
      "url": "https://finnhub.io/api/news?id=09dc89d140df93db072192a7dce137b123b4ee5e8199dc97540e0c129bafedd7"
    }
  },
  {
    "ts": null,
    "headline": "Earnings Scheduled For February 10, 2026",
    "summary": "",
    "url": "https://finnhub.io/api/news?id=34cdaa667719ebb868aab7df7cb89a13599504085c8554c65ca0fc74f16d2453",
    "source": "Benzinga",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770707478,
      "headline": "Earnings Scheduled For February 10, 2026",
      "id": 139029023,
      "image": "https://cdn.benzinga.com/files/images/story/2025/11/06/earnings_scheduled_1.jpg?width=2048&height=1536",
      "related": "GILD",
      "source": "Benzinga",
      "summary": " ",
      "url": "https://finnhub.io/api/news?id=34cdaa667719ebb868aab7df7cb89a13599504085c8554c65ca0fc74f16d2453"
    }
  },
  {
    "ts": null,
    "headline": "Gilead Sciences: Buy This Stock For Both Dividend And Growth",
    "summary": "Gilead Sciences: Buy This Stock For Both Dividend And Growth",
    "url": "https://finnhub.io/api/news?id=e81d72ae20afbebf3fb8841caae7adbb69cb25fe0e1e1f62e222e0a30a1acee9",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770702333,
      "headline": "Gilead Sciences: Buy This Stock For Both Dividend And Growth",
      "id": 139028076,
      "image": "",
      "related": "GILD",
      "source": "SeekingAlpha",
      "summary": "",
      "url": "https://finnhub.io/api/news?id=e81d72ae20afbebf3fb8841caae7adbb69cb25fe0e1e1f62e222e0a30a1acee9"
    }
  },
  {
    "ts": null,
    "headline": "2 Intriguing Medical Stocks to Watch as Q4 Results Approach: EXEL, GILD",
    "summary": "With their Q4 results approaching after-market hours on Tuesday, February 10, Exelixis (EXEL) and Gilead Sciences (GILD) are two top-performing medical stocks to consider.",
    "url": "https://finnhub.io/api/news?id=3508e226674f2f72eb01a589cd4b3b76d84521d5624116d77046f1c865dbbd2e",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770682320,
      "headline": "2 Intriguing Medical Stocks to Watch as Q4 Results Approach: EXEL, GILD",
      "id": 138974356,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "GILD",
      "source": "Yahoo",
      "summary": "With their Q4 results approaching after-market hours on Tuesday, February 10, Exelixis (EXEL) and Gilead Sciences (GILD) are two top-performing medical stocks to consider.",
      "url": "https://finnhub.io/api/news?id=3508e226674f2f72eb01a589cd4b3b76d84521d5624116d77046f1c865dbbd2e"
    }
  }
]